NEW YORK (GenomeWeb) – Response Genetics today said it has executed a commercial agreement with the Knight Diagnostic Laboratories at Oregon Health & Science University to launch a next-generation sequencing-based lung cancer panel.
The Knight Diagnostic-developed panel provides "full gene sequencing of the actionable genes for lung cancer rather than detection only of so-called hot spots," Response Genetics said. It added that it expects to market the panel immediately.
Financial and other terms of the agreement were not disclosed.
The deal moves Response Genetics into the NGS space, and the Los Angeles-based molecular diagnostics firm's test portfolio can now analyze actionable genetic markers across six different tumor types and four different testing modalities, it said.
In a statement Response Genetics CEO said that with the addition of the Knight Diagnostic panel, the firm has a "differentiated product offering that includes gene mutation, amplification, and translocation data, as well as RNA expression-based data. We believe the use of multiple technology platforms enables us to provide truly comprehensive, actionable information for cancer therapy selection."